




RealRate

MEDICINAL PRODUCTS 2016

Chemours Co
Rank 33 of 49





RealRate

MEDICINAL PRODUCTS 2016

Chemours Co
Rank 33 of 49



The relative strengths and weaknesses of Chemours Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chemours Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 5.7% points. The greatest weakness of Chemours Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 85% points.

The company's Economic Capital Ratio, given in the ranking table, is 85%, being 51% points below the market average of 136%.

Input Variable	Value in 1000 USD
Assets, Current	2,301,000
Assets, Non-Current	644,000
General and Administrative Expense	632,000
Goodwill	176,000
Liabilities, Current	1,466,000
Liabilities, Non-Current	4,468,000
Other Assets	0
Other Compr. Net Income	-244,000
Other Expenses	5,154,000
Other Liabilities	234,000
Other Net Income	76,000
Other Revenues	5,717,000
Property, Plant and Equipment, Net	3,177,000
Research and Development	97,000

Output Variable	Value in 1000 USD
Liabilities	6,168,000
Assets	6,298,000
Expenses	5,883,000
Revenues	5,717,000
Stockholders Equity	130,000
Net Income	-90,000
Comprehensive Net Income	-212,000
BaseVar	12,193,000
ECR before LimitedLiability	-0.54%
Economic Capital Ratio	85%